학술논문
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.
Document Type
Article
Author
Eggermont, Alexander M. M.; Kicinski, Michal; Blank, Christian U.; Mandala, Mario; Long, Georgina V.; Atkinson, Victoria; Dalle, Stéphane; Haydon, Andrew; Meshcheryakov, Andrey; Khattak, Adnan; Carlino, Matteo S.; Sandhu, Shahneen; Larkin, James; Puig, Susana; Ascierto, Paolo A.; Rutkowski, Piotr; Schadendorf, Dirk; Boers-Sonderen, Marye; Di Giacomo, Anna Maria; van den Eertwegh, Alfonsus J. M.
Source
NEJM Evidence; Nov2022, Vol. 1 Issue 11, p1-12, 12p
Subject
Language
ISSN
27665526
Abstract
Copyright of NEJM Evidence is the property of MMS Publications and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)